Research Square • Jack Swain, Davis Carter, Leonardo Vando et al.
Among 13,963 adults with moderate-to-severe sleep disturbances who received at-home ketamine-assisted therapy for depression, 67.4% showed at least a 1-point improvement on a single sleep-related item from a depression screening tool after two sessions. By session six, 76.8% of completers met that threshold, and the average score dropped 48.8% from baseline. However, the study could not separate sleep changes from mood improvement because all participants were treated for depression and no control group was included. Side effects were reported by 3.7% to 5.0% of participants across sessions.
Christopher P. Albertyn, Jeremie Richard, Ron Joseph Shore et al.
preprint
Demoralization syndrome affects about one in five Canadians with advanced cancer, marked by helplessness, hopelessness, and loss of meaning, and is linked to a greater desire for hastened death and worse outcomes, but it is underrecognized and undertreated. Pharmacological treatments fail to address its existential roots, and psychosocial therapies are underfunded and not universally effective. Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) combines mindfulness training with psilocybin's neuroplastic effects, but its traditional one-on-one delivery limits scalability. The authors argue that group-based MB-PAT could bridge this gap by leveraging existing group therapy infrastructure and therapist familiarity with mindfulness, offering a scalable, equity-focused model for publicly funded Canadian oncology. The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) is highlighted as a key initiative to generate evidence and capacity.
SSRN Electronic Journal • Robin Sandell, Adele Lafrance, Olivia Gosseries et al.
In three people with incomplete spinal cord injuries who self-medicated with psilocybin, improvements in motor function, muscle activation, and strength were reported. One person with a C4–C5 injury noted better gait automaticity; another with a T7 injury regained activation of a previously non-responsive hamstring muscle; a third with a T12 injury experienced rapid strength gains and enhanced proprioceptive awareness. All three reported psychological benefits such as increased wellbeing, motivation for recovery, and improved adjustment. Benefits appeared greatest in partially innervated muscles and diminished after stopping psilocybin. Temporary spasticity was the only adverse effect. The authors suggest psilocybin may enhance recovery by amplifying existing neural pathways and call for controlled clinical trials.
Research Square • Alice Le Berre
In adults with treatment-resistant depression, esketamine was associated with early microstructural changes in the dentate gyrus of the hippocampus: reduced fractional anisotropy and increased orientation dispersion index, consistent with greater dendritic complexity. Lower baseline left-dentate gyrus fractional anisotropy correlated with greater improvement at two weeks, and a decrease in fractional anisotropy over that period also correlated with improvement. These changes suggest esketamine may promote hippocampal plasticity, and baseline diffusion MRI metrics could serve as candidate biomarkers for treatment response. The study included 12 adults with treatment-resistant depression and 24 matched controls, but larger studies are needed.
bioRxiv (Cold Spring Harbor Laboratory) • Lucas Dwiel, Angela Henricks, Elise Bragg et al. • 1 citation
preprint
Lysergic acid diethylamide (LSD) acutely reduces low-frequency electrical activity across the brain in rats, an effect that returns to normal after 24 hours. However, brain stimulation applied during a window of heightened neuroplasticity 24 hours after LSD produces larger and distinct changes in brain activity compared to stimulation after a placebo. This proof-of-concept finding suggests that psychedelic drugs may work in combination with brain stimulation to achieve enhanced effects on brain activity, with future work needed to assess impacts on behavior.
Pharmacology, biochemistry, and behavior • August 1, 2026 • Mengyang He, Zhifei Shi, Ruijie Zhan et al.
Depression involves multiple dysfunctions across brain systems, including emotional-cognitive circuits, stress hormone regulation, neurotransmitter systems, and neuroplasticity. This review argues that the BDNF/CREB signaling pathway acts as a central hub connecting these systems. It explains how genetic variations, stress-related epigenetic changes, and microRNA regulation affect this pathway, which in turn influences brain plasticity, stress toxicity, and neurotransmitter balance. The review also describes how antidepressants like ketamine, rTMS, and SSRIs work by activating this pathway, supporting its potential as a biomarker and treatment target. Limitations and future directions integrating multiomics and neuroimaging are discussed, reconceptualizing depression as a network disorder centered on BDNF/CREB signaling.
Hearing research • August 1, 2026 • Shuhan Lu, Zhixin Zhang, Xinmiao Xue et al.
Tinnitus, the perception of sound without an external source, lacks effective treatments. Psilocybin, a psychedelic, shows promise by activating 5-HT2A receptors, boosting glutamate release, and upregulating BDNF, which increases dendritic spine density and synaptic proteins in the hippocampus and prefrontal cortex, restoring neural plasticity. This review connects these neuroplasticity mechanisms to tinnitus-related neural changes, highlighting psilocybin's regulatory effects on excitatory (glutamate, dopamine) and inhibitory (GABA) neurotransmitters and their receptors, suggesting a novel therapeutic pathway.
Zenodo (CERN European Organization for Nuclear Research) • July 13, 2026 • Vladlena Mayorova
Atoms from a dead organism re-enter the global biogeochemical cycle and may carry an informational resonance—a trace of the previous host's physiological, emotional, and cognitive states. When these atoms are incorporated into a new organism during early development, this resonance could shape behavioral patterns, sensory preferences, emotional reactions, and unexplained phobias. The hypothesis draws on the conservation of mass, epigenetics, quantum entanglement, and over 2,500 documented cases of children's past-life memories. A thought experiment, the 'Girl from 1900,' illustrates the proposed atomic transmission. The paper suggests experimental tests, including epidemiological studies and isotopic labeling in animals, but does not claim proof.
Journal of psychopharmacology (Oxford, England) • July 13, 2026 • Todd D Gould, Sanjay J Mathew, Maurizio Fava et al.
A new pharmacological model called event-driven pharmacology (EDP) is described, in which a plastogen—a drug that induces lasting neural plasticity—produces sustained effects after only transient binding, unlike traditional drugs that require continuous receptor occupancy. Plastogens such as ketamine and classical psychedelics can trigger metaplasticity, priming synapses to respond to later stimuli long after the drug has left the body. Dosing such drugs to maintain constant target occupancy may paradoxically reduce benefits and increase side effects. The EDP model calls for new drug development, dosing strategies, and biomarkers to harness the therapeutic potential of plastogens for depression and other synaptic disorders.
Translational Psychiatry • July 11, 2026 • Moira G. Semple, Sarah E. Mennenga, Ryan Smith et al.
Ketamine and MDMA, compounds known as psychoplastogens, show therapeutic potential for mood and trauma-related disorders, but their molecular mechanisms are not fully understood. In a study analyzing blood samples from 20 ketamine-treated participants and saliva samples from 16 MDMA-treated participants, DNA methylation changes were examined using a Brain-Epigenome-Wide Association Study targeting brain-relevant genes. Ketamine was associated with 405 significantly altered genes and 169 functional networks, while MDMA was linked to 346 altered genes and 183 networks. Both compounds converged on pathways related to neuroplasticity and neuroimmune regulation, suggesting they induce peripheral epigenetic changes that engage molecular pathways relevant to psychiatric health.